New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

KARDIGAN INC

KARD

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

11.54 0.98 −7.83%

After hours trading: 11.54, unchanged, last trade Fri 4:01pm Eastern.

Market cap
$1.2B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−187.2%
Net debt / EBITDA
1.7×
Payout ratio
—
Dec '24 Dec '25
Current Ratio
6.07 9.20
Net Debt/EBITDA
0.51 1.70
Debt/Equity
0.00 0.00
ROE
— 115.10%
ROA
— (84.47%)
ROIC
0.00% 0.00%
Return on Tangible Assets
(201.32%) (61.07%)
Free Cash Flow per Share
(2.05) (12.07)
Book value per Share
(8.25) (19.35)
Free Cash Flow
(20.63) (156.20)
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 18, 2026